We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 25, 2021

Adjuvant Gefitinib Therapy for Early Stage EGFR-Mutant NSCLC

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
J. Clin. Oncol 2020 Dec 17;[EPub Ahead of Print], WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu, YC Wei, YY Liu, C Chen, Y Cheng, R Yin, F Yang, SX Ren, XF Li, J Li, C Huang, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu, P Yu, BH Wang, HT Ma, JJ Yang, HH Yan, XN Yang, SY Liu, Q Zhou, YL Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading